Description

Favipiravir is an inhibitor of influenza viruses A, B, and C (IC₅₀s: A = 0.03- 0.20 µg/mL H1N1; 0.01-0.30 H2N2; 0.08-0.48 H3N2; 0.14-0.15 H4N2; 0.24-1.60 H7N2; 0.20-0.82 H5N1; 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir^1-3 . It displays no cytotoxicity in a variety of cell lines. Selectively inhibits viral RNA-dependent RNA polymerase⁴ . Displays activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses⁵ . In clinical trials for treatment of SARS-CoV-2^6,7.

References

• "In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705"

• "Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates"

• "In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses"

• "Mechanism of Action of T-705 against Influenza Virus"

• "Favipiravir (T-705), a novel viral RNA polymerase inhibitor"

• "Discovering drugs to treat coronavirus disease 2019 (COVID-19)"

• "A Review of SARS-CoV-2 and the Ongoing Clinical Trials"

Not for human therapeutic use or for medicinal purposes. For research applications only.